(Q37431609)

20 August 2017

1 reference

title

Targeted therapies in multiple myeloma (English)

1 reference

20 August 2017

2

Andreas Charidimou

0 references

Efstathios Kastritis

object named as

Efstathios Kastritis

1

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

4

0 references

author name string

Andreas Charidimou

2

1 reference

20 August 2017

Andreas Varkaris

3

1 reference

20 August 2017

publication date

17 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

4

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

23-36

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-008-0102-9

20 August 2017

exact match

0 references

cites work

Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-008-0102-9

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

12 December 2020

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

12 December 2020

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

1 reference

12 December 2020

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

1 reference

12 December 2020

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling

1 reference

12 December 2020

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

1 reference

12 December 2020

Myeloma bone disease and proteasome inhibition therapies.

1 reference

12 December 2020

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

1 reference

12 December 2020

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

12 December 2020

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action

1 reference

12 December 2020

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

12 December 2020

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

1 reference

12 December 2020

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

12 December 2020

mTOR inhibitors in the treatment of cancer

1 reference

12 December 2020

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

1 reference

12 December 2020

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival

1 reference

12 December 2020

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

1 reference

12 December 2020

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

1 reference

12 December 2020

Clinical development of histone deacetylase inhibitors as anticancer agents

1 reference

12 December 2020

Immunomodulation by thalidomide and thalidomide analogues

1 reference

12 December 2020

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica

1 reference

12 December 2020

The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells

1 reference

12 December 2020

Hsp90 inhibitors in the clinic

1 reference

12 December 2020

High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies

1 reference

12 December 2020

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

1 reference

12 December 2020

Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

1 reference

12 December 2020

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

1 reference

12 December 2020

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

1 reference

12 December 2020

Advances in oral therapy for multiple myeloma.

1 reference

12 December 2020

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

1 reference

12 December 2020

Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.

1 reference

12 December 2020

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

1 reference

12 December 2020

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

1 reference

12 December 2020

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

12 December 2020

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

12 December 2020

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

12 December 2020

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

1 reference

12 December 2020

Managing and exploiting stress in the antibody factory.

1 reference

12 December 2020

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

1 reference

12 December 2020

From the bench to the bedside: emerging new treatments in multiple myeloma

1 reference

12 December 2020

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

1 reference

12 December 2020

Endothelial cells and VEGF in vascular development

1 reference

12 December 2020

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

12 December 2020

Thalidomide: a novel template for anticancer drugs

1 reference

12 December 2020

Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway.

1 reference

12 December 2020

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

1 reference

12 December 2020

The malignant clone and the bone-marrow environment

1 reference

12 December 2020

Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

1 reference

12 December 2020

Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.

1 reference

12 December 2020

Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner

1 reference

12 December 2020

CD40 ligand triggers interleukin-6 mediated B cell differentiation

1 reference

12 December 2020

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

12 December 2020

1 reference

12 December 2020

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

1 reference

12 December 2020

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

1 reference

12 December 2020

Identification and validation of novel therapeutic targets for multiple myeloma

1 reference

12 December 2020

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

12 December 2020

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

12 December 2020

Molecular and biological role of CD40 in multiple myeloma

1 reference

12 December 2020

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

1 reference

12 December 2020

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

12 December 2020

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

1 reference

12 December 2020

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

1 reference

12 December 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

12 December 2020

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

12 December 2020

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

1 reference

12 December 2020

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

1 reference

12 December 2020

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

1 reference

12 December 2020

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

1 reference

12 December 2020

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death

1 reference

12 December 2020

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

1 reference

12 December 2020

Advances in biology of multiple myeloma: clinical applications

1 reference

12 December 2020

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

1 reference

12 December 2020

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

1 reference

12 December 2020

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

1 reference

12 December 2020

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

12 December 2020

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

1 reference

12 December 2020

Clinical activity of tipifarnib in hematologic malignancies

1 reference

12 December 2020

Interleukin-6 in human multiple myeloma.

1 reference

12 December 2020

Cytokines and signal transduction

1 reference

12 December 2020

IGF1R signalling and its inhibition

1 reference

12 December 2020

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

1 reference

12 December 2020

A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145

1 reference

12 December 2020

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

1 reference

12 December 2020

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

12 December 2020

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

1 reference

12 December 2020

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

1 reference

12 December 2020

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

1 reference

12 December 2020

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

12 December 2020

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

1 reference

12 December 2020

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

1 reference

12 December 2020

Hsp90: a novel target for cancer therapy

1 reference

12 December 2020

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

1 reference

12 December 2020

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

1 reference

12 December 2020

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

1 reference

12 December 2020

Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells

1 reference

12 December 2020

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma

1 reference

12 December 2020

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

1 reference

12 December 2020

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

1 reference

12 December 2020

Antimyeloma activity of heat shock protein-90 inhibition.

1 reference

12 December 2020

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

1 reference

12 December 2020

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

1 reference

12 December 2020

Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment

1 reference

12 December 2020

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

1 reference

12 December 2020

Prognostic value of bone marrow angiogenesis in multiple myeloma

1 reference

12 December 2020

Angiogenesis and anti-angiogenesis in hematological malignancies

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

12 December 2020

Novel anti-myeloma agents and angiogenesis.

1 reference

12 December 2020

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

12 December 2020

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor

1 reference

12 December 2020

10.1007/S11523-008-0102-9

Identifiers

DOI

1 reference

20 August 2017

1 reference